RxDoctor Payments Data

Melodie Young

Adult Health · Dallas, TXNPI 1356379218

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Lilly USA, LLC at 36.6% of the total. Among adult health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$699,835in general payments, 2019–2025

Across 2,026 payments — averaging $345.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$256K
  • Arcutis Biotherapeutics, Inc.$107K
  • Johnson & Johnson$55K
  • UCB, Inc.$49K
  • LEO Pharma Inc.$42K
  • Sun Pharmaceutical Industries Inc.$35K
  • plus $156K from 29 others
$7,046in research payments, 2019–2025

Across 2 payments — averaging $3522.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$5K
  • Novartis$2K

What the payments were for

  • Consulting fees$181,68026%
  • Speaking & faculty fees$403,74858%
  • Travel & lodging$79,81111%
  • Food & beverage$33,8085%
  • Education$7870%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$699,835 in reported general payments places this provider in the 95th percentile of 933 adult health providers in Texas.

See all adult health providers in Texas

Medicare billing

Part B allowed, 2024
$2,707
Medicare patients
18
Services billed
40

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$90,571
OtezlaApremilast14$67,694
Fluorouracil74$4,270
Betamethasone Dipropionate69$3,078
Clobetasol Propionate46$2,197
Doxycycline Hyclate99$2,171
Mometasone Furoate83$1,612
Metronidazole34$1,589
Acitretin17$1,500
ValacyclovirValacyclovir Hcl40$948
Triamcinolone Acetonide83$785
Ciclopirox26$780
MethotrexateMethotrexate Sodium38$705
Fluticasone Propionate36$540
Ketoconazole28$487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$28,187$67,69414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 933 adult health providers in Texas.

Other adult health in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →